# Convalescent Plasma to Limit Coronavirus Associated Complications: Randomized Blinded Phase 2 Study Comparing Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 Hospitalized Patients

> **NIH NIH UL1** · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2020 · $5,391,810

## Abstract

PROJECT SUMMARY
The proposed administrative supplement to the Miami Clinical and Translational Science Institute (CTSI) is a
randomized blinded placebo-controlled trial to evaluate the efficacy of treatment with convalescent plasma
(CP) in hospitalized patients with COVID-19. Studies have shown that CP is safe for transfusion in COVID-19
patients. However, this trial was developed to obtain scientific evidence to support or reject the hypothesis that
CP may be a therapeutic option for COVID-19. The hypothesis underpinning this trial is that compared to
placebo, administration of CP will avert respiratory deterioration, the main cause of death, and improve clinical
status in patients hospitalized with COVID-19. This trial is being conducted across several sites that have
experienced rapidly rising numbers of COVID-19 cases, including Miami, Florida, New York City, New York,
and Houston Texas. Miami is the new epicenter of the COVID-19 pandemic in the United States, and one of
the global hot spots. This study is within the scope of the existing CTSA award, with its focus on network trials
and rapid site initiation and team science, and leverages the Miami CTSI’s focus on mobilizing resources in
response to rapidly emerging infectious diseases, proven during the Zika virus in 2015. Miami will serve as a
new site in this quickly designed and launched trial, building upon the work already done in NYC to develop a
multicenter, well-powered Phase 2 trial via regional collaborations and CTSA consortium partnerships.

## Key facts

- **NIH application ID:** 10223746
- **Project number:** 3UL1TR002736-03S1
- **Recipient organization:** UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
- **Principal Investigator:** Olveen Carrasquillo
- **Activity code:** UL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $5,391,810
- **Award type:** 3
- **Project period:** 2018-06-28 → 2023-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10223746

## Citation

> US National Institutes of Health, RePORTER application 10223746, Convalescent Plasma to Limit Coronavirus Associated Complications: Randomized Blinded Phase 2 Study Comparing Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 Hospitalized Patients (3UL1TR002736-03S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10223746. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*